CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Michelson Diagnostics, Ltd. in a Series A2 financing raising £1,977,779. The round was led by Octopus Investments and supported by Catapult Venture Managers Ltd, London Business Angels and several individual angel investors.
Michelson Diagnostics Ltd. (Orpington, United Kingdom) is a privately held diagnostic imaging company focused on the diagnosis and treatment-management of non-melanoma skin cancer (“NMSC”). The Company product, VivoSight® OCT, is a diagnostic imaging device using multi-beam optical coherence tomography (“OCT”), enabling dermatologists to produce a real-time, continuous high-resolution scanned images up to 2 millimetres beneath the surface of the skin. This revolutionary technology offers a viable alternative to biopsies as it allows dermatologists to diagnose and discuss treatment-options with patients in a single visit, thus offering improved clinical outcomes, healthcare economics and patient experience. Moreover, VivoSight® enables dermatologists to consider topical therapeutic options as an alternative to excising the NMSC lesion by ensuring in a follow-up scan that this treatment course has been successful. For more information visit www.michelsondiagnostics.com or www.vivosight.com
CATALYSIS Advises Life Science Innovators. Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK.